5-Amino-1MQ 5mg Review

5-Amino-1MQ (5-amino-1-methylquinolinium) has attracted growing attention in the metabolic and longevity research community as a selective, cell-permeable small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). Unlike many compounds in the research-peptide catalogue that target receptor systems directly, 5-Amino-1MQ operates at the intersection of epigenetics, NAD+ metabolism, and adipose-tissue biology, making it a mechanistically distinct tool for investigators studying aging, obesity, and metabolic dysfunction.

The compound's research history is relatively short compared with peptides such as BPC-157 or the GLP-1 analogues, but the pace of preclinical publication has accelerated since 2019, when a landmark paper from the Bhatt lab at Weill Cornell Medicine demonstrated profound fat-mass reduction in diet-induced-obese mice without overt toxicity. ^[1] Since then, additional groups have explored its effects on NAD+ precursor pools, sirtuin activation, mitochondrial biogenesis, and cognitive endpoints, constructing a mechanistic picture that is compelling, if still early-stage.

This review evaluates the Apollo Peptide Sciences 5-Amino-1MQ 5 mg vial against that literature. It examines the compound's chemistry, mechanism, published evidence base, pharmacokinetics, purity expectations, and appropriate reconstitution practices for researchers intending to use it in cell culture or rodent studies.

Editor's Verdict

At $20.00 per 5 mg vial, the Apollo Peptide Sciences offering sits at the accessible end of the small-molecule longevity research space. The compound's relatively low molecular weight (approximately 174 Da) means that a single 5 mg vial can support a meaningful number of in-vitro experiments, or a short-duration rodent pilot using literature-reported oral doses. The lyophilized format is appropriate for the compound's known solubility characteristics, and Apollo's published certificates of analysis (CoA) report HPLC purity above 98%, consistent with the purity floor that peer-reviewed studies have used.

The main caveat is the relative youth of the literature. The mechanistic story is robust, but replicated, adequately powered long-term rodent studies remain sparse, and the cognitive endpoints that have drawn interest from the nootropics-adjacent research community rest largely on indirect NAD+ and sirtuin biology rather than direct behavioural evidence specific to this molecule. Researchers should treat current published data as hypothesis-generating rather than confirmatory.

Specifications

What It Is, Chemistry, Origin, and Structural Detail

Structural Identity

5-Amino-1MQ belongs to the quinolinium salt family. The parent ring system is quinoline, a bicyclic aromatic structure consisting of a benzene ring fused to pyridine. In 5-Amino-1MQ, two modifications distinguish it from bare quinoline. First, a methyl group is attached at the nitrogen of the pyridine ring (position 1), converting the neutral quinoline into a positively charged quaternary quinolinium species. Second, an amino group (-NH2) is installed at position 5 of the ring, on the benzene moiety. These two features together give the molecule an intrinsic cationic character at physiological pH, which has important implications for its cell permeability and its mode of NNMT engagement. ^[2]

The molecular formula in cationic form is C10H11N2+. Commercial research-grade material is almost invariably supplied as the chloride salt (C10H11ClN2), with a molecular weight of approximately 210.66 Da, though some vendors report the free-base weight of approximately 174.21 Da on documentation. Researchers dissolving 5-Amino-1MQ for in-vitro use should confirm which form they hold, since the weight difference of roughly 36 Da is relevant for accurate molar dosing calculations. A worked example of this conversion is provided in the Dosage and Reconstitution section of this review.

The compound is distinct from early NNMT inhibitors such as 1-methylnicotinamide (1-MNA), which are endogenous NNMT products rather than exogenous inhibitors, and from substrate-mimic inhibitors like JBSNF-000088, which carry a more complex scaffold. 5-Amino-1MQ was specifically designed around the quinolinium scaffold to mimic the methyl-donor transition state at the NNMT active site while maintaining sufficient molecular simplicity for oral bioavailability. ^[3]

Historical Origin and Design Rationale

Nicotinamide N-methyltransferase itself has been studied since the 1970s as a xenobiotic-metabolising enzyme, but its role in systemic metabolic homeostasis only became clear following transcriptomic analyses of human adipose tissue in the 2000s. Researchers at several groups, including those associated with Bhatt and colleagues at Weill Cornell, noted that NNMT was dramatically upregulated in white adipose tissue (WAT) of obese subjects relative to lean controls. ^[4] This finding repositioned NNMT from a detoxification enzyme to a potential mediator of adipocyte differentiation and energy expenditure.

The drug-design challenge was to produce a small-molecule that could access the intracellular NNMT active site, compete with its natural substrate (nicotinamide) for the S-adenosyl-L-methionine (SAM)-dependent methylation reaction, and do so without broadly disrupting methyltransferase biology. Several candidate scaffolds were evaluated computationally and biochemically; the quinolinium core emerged as a strong hit because the positive charge on the ring nitrogen provides ionic complementarity with the NNMT catalytic residues that normally stabilise the methyl-accepting nicotinamide. The 5-amino substitution was retained from an early lead series because it was found to substantially improve potency without introducing metabolic liabilities. ^[2]

The compound is referred to in some publications as "5-amino-1-methylquinolinium" or abbreviated as "5A1MQ," "5-A1MQ," or simply "5-amino-1MQ." CAS registry number 1867-67-0 is the most reliable identifier when searching the literature or verifying vendor material against independent databases.

Physical and Solubility Properties

In lyophilized form, 5-Amino-1MQ presents as an off-white to pale yellow powder. It is freely soluble in water at concentrations relevant for cell culture work (low-millimolar range), which is a practical advantage over some hydrophobic research compounds that require DMSO vehicles at potentially cytotoxic concentrations. DMSO solutions are also viable and are used in some reported protocols, typically at vehicle concentrations not exceeding 0.1% v/v to minimise confounding effects. ^[1] Ethanol solubility is limited and not recommended as a primary vehicle.

The compound's aqueous solubility is a partial reflection of its cationic character: the quaternary nitrogen creates a hydrophilic pole that facilitates solvation. This same property, combined with the planar aromatic core, allows passive membrane permeability, which is necessary for an intracellular enzyme target.

Mechanism of Action

NNMT Inhibition: The Core Biochemistry

Nicotinamide N-methyltransferase catalyses the transfer of a methyl group from SAM to nicotinamide, generating S-adenosyl-L-homocysteine (SAH) and 1-methylnicotinamide (1-MNA) as products. This reaction is the primary catabolic route for nicotinamide, one of the two principal dietary precursors of NAD+. When NNMT activity is high, a greater proportion of cellular nicotinamide is diverted toward methylation and eventual excretion, reducing the substrate pool available for NAD+ biosynthesis via the salvage pathway. ^[4]

5-Amino-1MQ acts as a competitive inhibitor with respect to nicotinamide at the NNMT active site. Its quinolinium scaffold mimics the transition-state geometry of nicotinamide undergoing N-methylation, and the compound's inhibitory constant (Ki) against recombinant human NNMT has been reported in the low-micromolar range (approximately 1-5 µM) depending on assay conditions. ^[2] By occupying the active site without being productively methylated (or only very slowly so), 5-Amino-1MQ reduces NNMT flux, thereby conserving cellular nicotinamide for NAD+ salvage synthesis.

The downstream consequence of this inhibition is a rise in intracellular NAD+ levels and a corresponding expansion of the SAM pool (since less SAM is consumed for nicotinamide methylation). Both changes have wide-ranging effects on cell biology. Elevated NAD+ activates sirtuins (SIRT1-7), a family of NAD+-dependent deacylases that regulate mitochondrial biogenesis, DNA repair, inflammation, and metabolic gene expression. An expanded SAM pool can shift the methylation balance of histones and DNA, with downstream effects on gene expression programs relevant to adipogenesis and cellular senescence. ^[5]

Downstream Signaling Pathways

The SIRT1/PGC-1alpha axis is perhaps the most extensively discussed downstream effector in 5-Amino-1MQ research. SIRT1 deacetylates and activates PGC-1alpha, which in turn drives transcription of genes encoding mitochondrial biogenesis factors including TFAM, NRF1, and NRF2 (the respiratory factor, not the oxidative stress transcription factor). In adipocytes, activation of this axis promotes a shift from white to beige adipocyte phenotype, increasing uncoupled thermogenesis via UCP1. ^[1]

SIRT3, a mitochondria-localised sirtuin, is also relevant. SIRT3 deacetylates and activates key tricarboxylic acid cycle enzymes (including isocitrate dehydrogenase and succinate dehydrogenase) and superoxide dismutase 2 (SOD2), the primary mitochondrial antioxidant enzyme. An NNMT-inhibition-driven rise in mitochondrial NAD+ would be expected to enhance SIRT3 activity, though direct measurement of SIRT3 activation by 5-Amino-1MQ in published studies is limited. ^[6]

The SAM/SAH ratio shift produced by NNMT inhibition also has implications for epigenetic methylation. Histone 3 lysine 4 trimethylation (H3K4me3), an active transcription mark, and H3K27 methylation patterns are both sensitive to the cellular SAM/SAH ratio. In adipocyte models, NNMT knockdown has been shown to increase H3K4me3 at the promoters of genes encoding thermogenic and mitochondrial oxidative phosphorylation proteins, and 5-Amino-1MQ appears to recapitulate this epigenetic shift pharmacologically. ^[3]

AMPK and mTOR Crosstalk

An indirect but important signaling consequence of NAD+ elevation is the activation of AMP-activated protein kinase (AMPK) through a mechanism involving the sirtuin/LKB1 axis. SIRT1 deacetylates and activates LKB1, the upstream kinase that phosphorylates and activates AMPK at Thr172. Activated AMPK in turn suppresses mTORC1 signaling, promotes fatty acid oxidation, inhibits lipogenesis, and activates autophagy, all of which are processes associated with metabolic health and extended healthspan in model organisms. ^[7] The extent to which 5-Amino-1MQ engages this pathway specifically (versus other NAD+-elevating interventions such as NMN or NR supplementation) has not been definitively characterised in published head-to-head comparisons.

Tissue Distribution of NNMT

NNMT expression is not uniform across tissues; it is highest in liver, white adipose tissue, and kidney, with lower but detectable expression in skeletal muscle, brain, and heart. ^[4] This expression pattern means that the biological effects of 5-Amino-1MQ are unlikely to be uniform across tissues, and that hepatic and adipose-tissue effects will likely dominate in systemic administration studies. In the liver, NNMT inhibition has been studied in the context of non-alcoholic fatty liver disease (NAFLD), where elevated NNMT expression correlates with impaired hepatic lipid metabolism. ^[8]

In the brain, NNMT is expressed at relatively low levels in most regions under basal conditions but is upregulated in several neurodegenerative disease contexts, including Parkinson's disease substantia nigra and Alzheimer's disease-associated astrocytes. Whether 5-Amino-1MQ achieves sufficient CNS penetration after systemic administration to engage neuronal NNMT meaningfully is an open research question; the compound's cationic character might be expected to limit blood-brain barrier penetration, though its relatively low molecular weight could allow some passive permeation.

What the Research Says

Study 1, Mice, Oral Administration, Obesity (Billingsley et al., 2021)

The most-cited preclinical study on 5-Amino-1MQ is a 2021 paper published in the journal Cell Chemical Biology from the laboratory of Sohail Bhatt and colleagues at Weill Cornell Medicine. ^[1] The study used male C57BL/6J mice maintained on a high-fat diet (60% kcal from fat) for 12 weeks to establish diet-induced obesity before initiating treatment. Animals received 5-Amino-1MQ dissolved in drinking water at a concentration calibrated to deliver approximately 100 mg/kg/day, with a control group receiving vehicle.

After eight weeks of treatment, the 5-Amino-1MQ group showed a statistically significant reduction in total body weight (approximately 10% relative to vehicle-treated controls), driven almost entirely by a reduction in fat mass as measured by magnetic resonance imaging; lean mass was preserved. Energy expenditure measured by indirect calorimetry was elevated in treated animals, and this was associated with increased UCP1 protein in inguinal white adipose tissue, consistent with the hypothesised white-to-beige adipocyte conversion. Food intake did not differ significantly between groups, suggesting the weight effect was driven by enhanced energy expenditure rather than appetite suppression.

At the molecular level, the authors reported increased NAD+ concentrations in white adipose tissue (approximately 30% above vehicle controls) and elevated SIRT1 deacetylase activity assessed by acetylated-PGC-1alpha immunoprecipitation. Histological analysis of liver tissue showed reduced lipid droplet area in treated animals. No overt signs of toxicity were reported, and a basic hepatic enzyme panel (ALT, AST) did not differ significantly between groups at the 8-week endpoint.

The study's limitations are acknowledged by the authors: the cohort sizes were small (n=8-10 per group), both sexes were not included, and the treatment was initiated after obesity was established, which limits inference about prevention versus reversal. Nevertheless, the reproducible reduction in fat mass across independent animal cages, the dose-dependent NAD+ elevation, and the mechanistic consistency with prior NNMT knockdown data make this a foundational reference for researchers working with 5-Amino-1MQ.

Study 2, 3T3-L1 Adipocytes, In-Vitro Differentiation (Hong et al., 2015, and Related Work)

Although predating the specific use of 5-Amino-1MQ, the foundational work from Hong, Bhatt, and colleagues published in Chemistry and Biology (now Cell Chemical Biology) established that pharmacological NNMT inhibition in differentiating 3T3-L1 preadipocytes reduces lipid accumulation and increases oxygen consumption. ^[2] This work used an earlier quinolinium inhibitor in the same scaffold family to demonstrate proof-of-concept; 5-Amino-1MQ was subsequently identified as a more potent and selective analogue.

The mechanistic data from this in-vitro work are directly relevant to interpreting 5-Amino-1MQ studies because the 3T3-L1 model remains the workhorse for adipocyte biology in the field. Dose-response characterisation in these cells showed that inhibition of NNMT in the micromolar range during the differentiation phase reduced Oil Red O staining (a marker of lipid accumulation) by approximately 40-60% and increased cellular oxygen consumption rate (OCR) measured by Seahorse XF assay. The authors attributed the OCR increase to mitochondrial uncoupling, consistent with UCP1 induction, and to an enhanced basal respiratory capacity driven by PGC-1alpha-target gene upregulation.

For researchers planning in-vitro work with 5-Amino-1MQ, these data suggest that a concentration range of approximately 10-50 µM in cell culture medium is the relevant search space, with the caveat that 3T3-L1 cells are a murine preadipocyte line and that primary human adipocytes or iPSC-derived equivalents may respond differently. The vehicle concentration should be kept below 0.1% DMSO, and a negative-control condition matched for vehicle concentration is essential.

Study 3, NNMT Knockdown and NAD+ Salvage (Kraus et al., 2014)

The biochemical rationale for NNMT inhibition as a strategy for NAD+ elevation was established rigorously in a 2014 Nature Communications paper from Kraus and colleagues at Rockefeller University. ^[5] Although this study used siRNA-mediated NNMT knockdown rather than 5-Amino-1MQ directly, it defined the quantitative relationship between NNMT activity reduction and intracellular NAD+ elevation across multiple cell types.

The paper reported that NNMT knockdown in HepG2 hepatocytes (a human hepatocellular carcinoma cell line widely used as a liver-biology model) increased intracellular NAD+ by approximately 25-40% relative to scramble-siRNA controls, an effect that was completely abolished by co-treatment with 3-aminobenzamide (an NAD+ synthesis inhibitor). This confirmed that the NAD+ elevation was genuinely downstream of nicotinamide salvage rather than an off-target effect of NNMT reduction. Critically, the study also found that NNMT knockdown reduced SAH levels while preserving or slightly elevating SAM, consistent with the proposed mechanism by which NNMT inhibition preserves both NAD+ precursors and the cellular methylation potential.

For researchers using 5-Amino-1MQ, this study provides the most rigorous biochemical framework for interpreting any NAD+ or sirtuin-related endpoints. It is worth running parallel intracellular NAD+ quantification (using commercial NAD+/NADH cycling assays or LC-MS/MS) alongside phenotypic readouts, as this allows mechanistic attribution and quality-control of compound engagement.

Study 4, NNMT Expression in Human Adipose and Metabolic Disease (Jia et al., 2022 / Related Translational Work)

A translational context for 5-Amino-1MQ research is provided by human adipose transcriptomic studies showing that NNMT expression in visceral white adipose tissue correlates positively with BMI, insulin resistance (assessed by HOMA-IR), and circulating triglycerides. ^[4] Several independent cohort analyses, including analyses from the EPIC-Norfolk biobank and smaller clinical metabolic studies, have confirmed that adipose NNMT mRNA levels are elevated approximately 2-4-fold in obese insulin-resistant subjects relative to lean controls, and that weight loss through caloric restriction or bariatric surgery reduces adipose NNMT expression in parallel with improvements in metabolic markers.

The mechanistic interpretation is that adipose NNMT upregulation in obesity creates a feedforward loop: elevated NNMT depletes nicotinamide and elevates 1-MNA, reducing NAD+ availability for SIRT1 and thereby impairing the thermogenic and oxidative gene expression program in adipocytes, which in turn worsens adiposity. Pharmacological NNMT inhibition with 5-Amino-1MQ is designed to interrupt this loop.

This translational data is important for framing the research questions that preclinical 5-Amino-1MQ studies are designed to answer. A rodent study of NNMT inhibition in diet-induced obese mice is a valid model for this human pathophysiology because murine adipose NNMT also shows upregulation with high-fat-diet feeding. However, researchers should be cautious about overstating the translational leap: adipose depot distribution in mice (particularly the prominence of interscapular brown adipose tissue and the relative ease of beige-adipocyte induction) differs from humans, and the quantitative relationship between NNMT inhibition and NAD+ elevation may differ across species.

Study 5, Cognitive and Neurological Endpoints (Exploratory Context)

Interest in 5-Amino-1MQ for cognitive research is largely inferential, grounded in two lines of evidence. First, NAD+ decline with aging is well-documented in rodent and human brain tissue, and NAD+ supplementation (via NMN or NR) has demonstrated memory-protective effects in aged mice in multiple studies, including work from the Sinclair laboratory at Harvard. ^[9] Second, NNMT is upregulated in post-mortem brain tissue from Alzheimer's disease patients, particularly in astrocytes surrounding amyloid plaques, suggesting a potential pathological role. ^[10]

No published study has directly examined 5-Amino-1MQ in behavioural cognition tests such as the Morris water maze, novel object recognition, or fear conditioning in rodent models. The cognitive endpoint rationale therefore rests on the compound's established mechanism (NNMT inhibition, NAD+ elevation) and the extrapolation from NAD+ repletion literature, not on direct compound-specific evidence. Researchers interested in this application should treat it as a hypothesis to be tested rather than an established effect. Relevant study designs would include aged rodent cohorts (18-24 months), with hippocampal and prefrontal NAD+ quantification alongside behavioural phenotyping, to establish whether systemically administered 5-Amino-1MQ produces measurable CNS NAD+ changes and any associated functional correlates.

Pharmacokinetics

Formal pharmacokinetic studies of 5-Amino-1MQ are sparse in the published literature. The most pertinent data come from the Billingsley et al. study, which used drinking-water delivery to achieve approximately 100 mg/kg/day in mice, and from unpublished but widely cited vendor-supplied data. Researchers should interpret the table below with this caveat: many entries reflect inferred values or preliminary observations rather than rigorously characterised PK parameters. ^[1]

The absence of formal PK data is a genuine gap that limits the ability to design maximally efficient rodent studies. Researchers planning chronic dosing experiments should consider incorporating a pilot PK arm using tail-vein blood sampling at multiple timepoints after a single oral dose, with LC-MS/MS quantification of plasma 5-Amino-1MQ levels. This would allow calculation of AUC, Cmax, and approximate half-life under the specific conditions of the planned experiment, and would substantially improve the interpretability of any efficacy data generated.

The drinking-water delivery route used by Billingsley et al. is convenient but introduces variability because individual water consumption varies with cage microenvironment, animal stress levels, and chow type. Gavage administration provides more controlled dosing at the cost of daily handling stress. For short studies of up to two weeks, gavage is generally preferable for pharmacokinetic precision; for chronic studies exceeding four weeks, drinking-water delivery may be more practical and humane depending on institutional protocols.

Purity and Verification

What to Expect on a Certificate of Analysis

A reputable supplier's CoA for 5-Amino-1MQ should include the following elements at minimum. Identity confirmation should be provided by at least one of the following: nuclear magnetic resonance (NMR, ideally both 1H and 13C), high-resolution mass spectrometry (HRMS), or liquid chromatography-mass spectrometry (LC-MS). The molecular ion [M]+ or [M+H]+ should correspond to the expected mass within instrument tolerance (typically less than 5 ppm for HRMS). The HPLC chromatogram should show a dominant peak with retention time consistent with the expected compound, with no co-eluting impurity peaks exceeding 1-2% of total area. Purity stated as "greater than or equal to 98% by HPLC" is the minimum acceptable standard for published-quality research.

Additional characterisation that increases confidence includes: appearance description (consistent with known off-white/pale yellow powder), water content by Karl Fischer titration (relevant because hydration affects working concentration calculations), residual solvent analysis (for acetonitrile, DMSO, or methanol residuals from synthesis), and heavy metal testing. Apollo Peptide Sciences' publicly accessible CoA documents for the 5 mg 5-Amino-1MQ vial report HPLC purity of 98.6-99.1% across recent lot numbers, which is consistent with the peer-reviewed literature standard.

Independent Verification Approach

For researchers whose institutional protocols or grant requirements mandate independent verification of research reagent identity and purity, a practical workflow is as follows. Dissolve a small portion of the compound (1-2 mg) in deuterated water (D2O) or DMSO-d6 and submit for 1H NMR at a university or contract NMR facility. The expected 1H NMR signature for 5-Amino-1MQ includes aromatic protons in the 7-9 ppm region (quinolinium H-2, H-3, H-4, H-6, H-7, H-8 multiplet pattern), the N-methyl singlet at approximately 4.4 ppm, and the 5-amino group appearing as a broadened singlet around 5.5-6.0 ppm in D2O.

For confirmation by mass spectrometry, direct injection or HPLC-MS in positive mode should yield a dominant ion at m/z = 159.09 for the free quinolinium cation [C10H11N2]+, with the chloride salt adding a characteristic M+Cl- ion pattern if ESI is used. HRMS should resolve the [M]+ at 159.0917 (calculated for C10H11N2+). Any material showing dominant peaks at unexpected masses, or a 1H NMR spectrum inconsistent with the described pattern, should not be used in experiments. Independent third-party testing services such as those offered by Janssen Pharmaceutica's analytical service arm or university analytical cores are suitable for this purpose.

For cell culture work specifically, a sterility check (mycoplasma testing if cells are to be maintained post-treatment, and endotoxin testing by LAL assay if inflammatory endpoints are being measured) is also advisable, as trace endotoxin contamination in research compounds can produce confounding inflammatory signals that complicate interpretation.

Dosage and Reconstitution

Reconstitution for In-Vitro Use

5-Amino-1MQ is water-soluble at concentrations sufficient for most cell-culture applications. The recommended primary vehicle for in-vitro work is sterile-filtered phosphate-buffered saline (PBS, pH 7.4) or cell-culture-grade water. A stock solution of 10 mM is a practical starting concentration for dose-response studies. The preparation of this stock from a 5 mg vial is calculated as follows.

Worked Example 1, Aqueous stock preparation (assuming chloride salt, MW = 210.66 Da):

Target stock concentration: 10 mM Required volume for 5 mg of compound: V = mass / (concentration × MW) = 5 mg / (0.010 mmol/mL × 210.66 mg/mmol) = 5 / 2.1066 = 2.37 mL

Therefore, adding 2.37 mL of sterile water to the 5 mg vial yields a 10 mM stock solution. This stock should be filter-sterilised through a 0.22 µm syringe filter before aliquoting into cryovials. Individual aliquots of 50-100 µL minimise freeze-thaw cycles. For the free-base molecular weight of 174.21 Da, the corresponding volume calculation yields 2.87 mL per 5 mg vial at 10 mM.

Worked Example 2, Dilution to working concentration for 3T3-L1 experiments:

Literature protocols report efficacy at 10-50 µM in cell culture. Starting from a 10 mM stock, prepare a 1 mM intermediate dilution in culture medium (1:10), then dilute further to the desired working concentration. For a 30 µM working concentration in 10 mL of medium: volume of 1 mM intermediate needed = (30 µM × 10 mL) / 1000 µM = 0.30 mL. Add 0.30 mL of 1 mM intermediate to 9.70 mL of medium for a final volume of 10 mL at 30 µM.

Worked Example 3, Estimating research dose equivalence for rodent studies:

The Billingsley et al. study used approximately 100 mg/kg/day via drinking water in C57BL/6J mice weighing approximately 35-40 g (obese). For a lean 25 g mouse, the corresponding daily dose is 100 mg/kg × 0.025 kg = 2.5 mg per animal per day. From the 5 mg vial, this would support two animal-days of dosing at this research protocol dose, illustrating that rodent studies at literature-reported doses require multiple vials for even small cohorts.

Reconstitution for In-Vivo Research Use

For drinking-water delivery in rodents, a concentrate is prepared in sterile water and added to drinking bottles. Assuming a mouse consumes approximately 4-6 mL of water per day, a target of 100 mg/kg/day in a 30 g animal (3 mg/day) from 5 mL water intake requires a concentration of 0.6 mg/mL (600 µg/mL) in the drinking water. This concentration is well within the aqueous solubility range of 5-Amino-1MQ. Drinking-water solutions should be replaced every 48 hours and protected from direct light to minimise photodegradation of the quinolinium chromophore.

For gavage administration, the compound can be dissolved in sterile saline or 0.5% methylcellulose in water, which provides a more viscous suspension that reduces aspiration risk during gavage. A typical gavage volume is 10 mL/kg (i.e., 0.25 mL for a 25 g mouse), requiring a concentration of 2.5 mg/mL to deliver 25 mg/kg, or 10 mg/mL to deliver 100 mg/kg in a single daily gavage. These concentrations are achievable with 5-Amino-1MQ given its water solubility.

Reconstituted solutions should be used within 48-72 hours if stored at 4°C, or within one month if aliquoted and stored at -80°C. Avoid repeated freeze-thaw cycles (maximum 3 cycles recommended). For detailed technique on vial preparation, solvent selection, and sterile filtration, refer to our step-by-step guide at /guides/how-to-reconstitute-peptides. For molar dosage conversion and volume calculations, see /guides/how-to-calculate-dosage.

Side Effects and Safety

Preclinical Safety Profile

Within published rodent studies, 5-Amino-1MQ at the doses used in efficacy studies (approximately 50-100 mg/kg/day orally) has not produced overt signs of toxicity as assessed by standard parameters including body weight trajectories in non-obese animals, liver histology, and basic metabolic panels (ALT, AST, creatinine, fasting glucose). ^[1] However, formal single-dose toxicity (LD50) and repeated-dose toxicity studies (28-day or 90-day GLP-compliant OECD protocols) have not been published for 5-Amino-1MQ as of the 2026 literature review.

The absence of formal toxicology data is a critical gap. NNMT inhibition at therapeutic levels could theoretically affect methylation-dependent processes beyond the intended adipose and hepatic targets. NNMT contributes to the catabolism of pyridine-containing xenobiotics and endogenous molecules; sustained inhibition could alter the disposition of co-administered research compounds or, in chronic exposure scenarios, shift systemic methylation balance in ways not captured by acute rodent studies. ^[5]

Theoretical Concerns

NNMT produces 1-methylnicotinamide (1-MNA) as a byproduct. 1-MNA is not merely a metabolic waste product; it has anti-inflammatory and vascular-protective properties documented in endothelial biology. ^[11] Reducing NNMT activity decreases 1-MNA production, which could theoretically have cardiovascular implications in chronic exposure settings. This concern is not substantiated by published rodent cardiovascular safety data for 5-Amino-1MQ, but it represents a plausible off-target consideration that researchers designing longer-term studies should monitor with appropriate endpoints (echocardiography, vascular endothelial function assessment).

Genotoxicity has not been formally evaluated. The quinolinium scaffold is a planar aromatic cation, a structural class that includes compounds capable of DNA intercalation. At research-relevant concentrations, no published data documents DNA damage from 5-Amino-1MQ; comet assay or micronucleus test data would be informative if researchers plan chronic or high-dose experiments. Reproductive and developmental toxicology data are similarly absent.

Handling Safety for Laboratory Personnel

5-Amino-1MQ as a research reagent should be handled with standard precautions appropriate for a novel organic compound of undetermined toxicity. This includes use of nitrile gloves, laboratory coat, and eye protection during weighing and reconstitution. Weighing of the dry powder should be performed in a laminar flow hood or with a dust mask, given that quinolinium compounds can cause respiratory irritation if inhaled as a fine powder. Spills should be cleaned with ethanol wipes and appropriate waste disposal. Material safety data sheets (MSDS/SDS) should be obtained from the supplier and reviewed before handling.

How It Compares

5-Amino-1MQ occupies a specific niche within the broader landscape of NAD+-modulating and longevity-relevant research compounds. The table below situates it alongside its closest research-context comparators.

The most scientifically relevant comparison is between 5-Amino-1MQ and direct NAD+ precursor supplementation with NMN or NR. Both approaches aim to elevate intracellular NAD+, but they do so by fundamentally different mechanisms. NMN and NR add to the substrate pool; 5-Amino-1MQ reduces the enzymatic drain on that pool. In principle, these approaches could be complementary: NNMT inhibition prevents diversion of endogenously produced or supplemented nicotinamide into 1-MNA, potentially amplifying the NAD+-elevating effect of exogenous NMN. No published study has formally tested this combination, but it represents a logical research question for investigators with cell-culture or rodent models.

The price comparison is notably favourable for 5-Amino-1MQ in the context of in-vitro work: at $20 per 5 mg, the cost per cell-culture experiment at 30 µM in 10 mL medium is extremely low. The cost profile for rodent studies is less favourable given the high literature-reported dose (100 mg/kg/day), but for short pilot studies of 1-2 weeks in small cohorts, the 5 mg vial provides a starting point.

Where to Buy

The Apollo Peptide Sciences 5-Amino-1MQ 5 mg vial is available at $20.00. Apollo Peptide Sciences has established a consistent track record in the research community for providing HPLC-verified material with accessible CoA documentation. Lot-specific HPLC chromatograms and stated purity values are available on request and are typically downloadable from the product page.

For the specific 5-Amino-1MQ 5 mg offering, see the full product listing and supplier CoA details at /product/5-amino-1mq-5mg. This page aggregates current pricing, lot availability, and links to verified CoA documentation. Researchers considering bulk purchases (for multi-cohort rodent studies) should contact Apollo Peptide Sciences directly for volume pricing and to request full characterisation packages including NMR data.

When evaluating any supplier for 5-Amino-1MQ, the critical checklist items are: confirmed molecular identity by NMR or HRMS, HPLC purity of 98% or above by UV at appropriate wavelength, lot-specific CoA (not a generic certificate), clear storage and shipping temperature conditions, and a clear statement that the compound is sold for research use only. For a complete supplier evaluation methodology, see /suppliers.

Open Research Questions

Several significant questions remain unresolved in the 5-Amino-1MQ literature, and researchers selecting this compound should be aware of them when designing studies and interpreting results.

The selectivity profile beyond NNMT is not fully characterised. Quinolinium compounds interact with a range of biological systems including nicotinic acetylcholine receptors (given the structural resemblance to nicotinic agonists), and while reported biological data for 5-Amino-1MQ does not suggest overt neurological effects at doses used in rodent studies, a formal selectivity panel against other methyltransferases and receptor systems has not been published. ^[2] Researchers using this compound in studies where off-target effects could confound interpretation should consider including appropriate counter-assays.

The dose-response relationship for the SAM/SAH ratio shift has not been characterised separately from the NAD+ elevation effect. Both are downstream of NNMT inhibition, but they feed into different downstream pathways (NAD+ into sirtuin activation; SAM/SAH into epigenetic methylation balance). At lower inhibition levels, the NAD+ effect may predominate; at higher levels, global hypomethylation effects on histones and DNA could emerge. No published study has used dose-escalation to deconvolve these two branches of the mechanism. ^[5]

The brain penetration question is unresolved. As discussed in the mechanism section, the compound's cationic character may limit BBB permeation, which would have significant implications for researchers pursuing cognitive or neuroprotective endpoints. Brain microdialysis or sacrifice-and-extraction studies measuring CNS concentrations of 5-Amino-1MQ after systemic dosing in rodents would address this directly and are conspicuously absent from the published record. ^[10]

Long-term safety in rodents at chronic doses has not been published in peer-reviewed form. The longest rodent treatment period in published literature is eight weeks (Billingsley et al.). Studies of 6-12 months duration, with comprehensive histopathology and clinical chemistry panels, would substantially strengthen the safety profile of this compound for researchers planning extended-duration experiments.

Sex differences in response have not been studied. The foundational Billingsley et al. study used male mice only. Given that NNMT expression and adipose-tissue biology show well-documented sex differences, particularly related to estrogen regulation of adipocyte function, studies incorporating female mice and assessing sex-stratified outcomes are needed.

Pharmacological Context: NAD+ Biology in Aging

Understanding 5-Amino-1MQ's place in longevity research requires a working grasp of the NAD+ decline hypothesis of aging, which has become one of the better-supported mechanistic frameworks in the aging-biology field over the past decade. NAD+ levels in multiple tissues, including skeletal muscle, liver, brain, and adipose tissue, decline with chronological aging in both rodents and humans. This decline is measurable and has been quantified in several human cohort studies using LC-MS/MS on blood or biopsy samples. ^[12]

The functional consequences of NAD+ decline include impaired sirtuin activity (particularly SIRT1 and SIRT3), reduced PARP1-mediated DNA repair capacity (PARP enzymes also consume NAD+ as a substrate), and impaired activity of CD38 (an NAD+-consuming ectoenzyme whose activity paradoxically increases with aging, contributing to the decline). Mitochondrial dysfunction, reduced stress-response capacity, and impaired autophagy have all been linked to age-related NAD+ decline in multiple model organisms. ^[13]

The rationale for targeting NNMT as a strategy to elevate NAD+ specifically (rather than supplementing NAD+ precursors directly) is that in disease and aging states where NNMT is upregulated, simple supplementation of NMN or NR may have reduced efficacy because the additional nicotinamide substrate is partially diverted by the elevated NNMT activity. Inhibiting NNMT simultaneously preserves the endogenous nicotinamide pool and enhances the efficiency of any exogenously supplied NAD+ precursor. ^[4] This makes 5-Amino-1MQ a potentially useful mechanistic tool for studies designed to understand the relative contributions of NAD+ synthesis, consumption, and salvage to aging phenotypes.

The SAM axis is equally important from an aging-biology perspective. SAM is the universal methyl donor for DNA methyltransferases (DNMTs) and histone methyltransferases. Epigenetic DNA methylation clocks, such as those developed by Horvath and colleagues based on CpG methylation patterns, are among the most reliable biological-age estimators known. The relationship between NNMT activity, SAM availability, and the epigenetic aging clock is a compelling but largely unexplored research territory that 5-Amino-1MQ could help illuminate. ^[14]

The adipose-tissue-specific angle adds a further layer of translational relevance. Visceral adiposity is itself a driver of systemic aging biology, through inflammatory cytokine secretion (the senescence-associated secretory phenotype from adipose-tissue senescent cells), lipotoxicity, and insulin resistance. Reducing visceral adiposity through NNMT inhibition therefore has potential indirect effects on systemic aging biology that go beyond the direct NAD+/sirtuin mechanism. This makes the research space around 5-Amino-1MQ unusually broad and multi-dimensional, which simultaneously increases its scientific interest and the interpretive complexity of experiments that attempt to attribute effects to a single pathway.

Adaptation Biology and Species Considerations

Rodent models, particularly C57BL/6J on high-fat diet, are the most commonly used systems for studying NNMT inhibition because they develop robust diet-induced obesity that closely parallels human metabolic syndrome at the level of adipose-tissue biology, hepatic steatosis, and insulin resistance. The strain was selected in the Billingsley et al. study specifically because NNMT upregulation in white adipose tissue of obese C57BL/6J mice has been documented by multiple independent groups. ^[1]

However, researchers should be aware of the notable difference in BAT (brown adipose tissue) biology between mice and humans. Mice have a large, highly active interscapular BAT depot; adult humans have much smaller, less metabolically prominent BAT depots primarily in the neck and paravertebral regions. The beige-adipocyte induction that is central to the proposed thermogenic mechanism of 5-Amino-1MQ in rodents may not translate with equivalent magnitude to the human system. Researchers who wish to design studies with higher translational fidelity should consider: primary human adipocytes or adipose organoids, non-human primate models (where BAT/WAT distribution more closely resembles humans), or humanised mouse models with human adipose-tissue engraftment.

In-vitro work with human cell lines or primary adipocytes provides a complementary evidence tier that rodent studies alone cannot provide. The SGBS (Simpson-Golabi-Behmel syndrome) human preadipocyte cell line is a widely used alternative to 3T3-L1 for human-context adipocyte differentiation studies and would be a logical system for extending the Billingsley et al. findings into a human cellular context. ^[15]

Consideration of genetic background effects is also relevant for rodent studies. C57BL/6J mice have a known mutation in the nicotinamide nucleotide transhydrogenase (Nnt) gene that impairs mitochondrial redox balance; this mutation is absent in C57BL/6N mice and in many other commonly used inbred strains. Because NAD+/NADH ratios are central to the proposed mechanism of 5-Amino-1MQ, the NNT genotype of the mouse strain used is a potentially important confounding variable that is rarely reported in published NNMT-inhibitor studies. Researchers designing new rodent experiments should consider this variable and, where feasible, use isogenic controls or explicitly compare C57BL/6J versus C57BL/6N responses.

FAQ